U.S. flag

An official website of the United States government

GTR Home > Tests > 24GENETICS DNA PANEL

Overview

Test name

Help

24GENETICS DNA PANEL (DNA-PANEL)

Purpose of the test

Help

This is a clinical test intended for Help: Predictive, Risk Assessment, Drug Response

Condition

Help

Loading data ......

Click Indication tab for more information.

How to order

Help

online ordering
Order URL Help: https://24genetics.com/en/shop

Specimen source

Buccal swab

Methodology

Help
Biochemical Genetics
XProtein expression
Microarray
  • Illumina HiScan™SQ system
  • Illumina Infinium HD HumanCytoSNP-12

Summary of what is tested

Loading data ......

Click Methodology tab for more information.

Clinical utility

Help

Not provided

Clinical validity

Help

no clinical validity

Citations

Not provided

Test services

Help
  • Custom Sequence Analysis

Suggested reading

  • USPSTF, 2019
    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force
  • USPSTF, 2013
    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation (See 2019 Update)
  • NCI PDQ, Breast and Gynecologic Cancers
    Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version
  • NCI PDQ, Cancer Genetics Counseling
    Cancer Genetics Risk Assessment and Counseling (PDQ®): Health Professional Version

Practice guidelines

  • NICE, 2024
    UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024
  • NICE, 2023
    UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023
  • NCCN, 2023
    Breast Cancer, NCCN Guidelines Version 4.2022
  • NCCN, 2022
    NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022
  • ACMG ACT, 2019
    American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.